Need help? Order a test

Are RGCC’s tests accredited?

Yes, all of our tests are carried out at our ISO-accredited laboratories, which are equipped with the latest technology and specialised software for data analysis.

Where is RGCC based?

RGCC is a global company with headquarters in Switzerland. RGCC is a global organisation, and we work in collaboration with branch offices and distributors to provide a worldwide service.

What happens when I order a test with RGCC?

You will first need to arrange an appointment with your personal healthcare provider or contact one from our international network. Please download this letter and take it along to your appointment. Your doctor will arrange to take a blood sample from you. This is sent to our world-leading laboratories where our scientists carry out a range of personalised tests on your sample. We create a profile of treatments that may benefit you and share this with you and your personal healthcare provider, so you can work together to develop a personalised approach to your diagnosis.

Will you send me the results directly?

Please review our patient information leaflet.

Do I need to go through my GP to get a test?

Please review our patient information leaflet.

Can RGCC test for BRAF drugs?

Yes. Onconomics and Onconomics Plus tests can be used for Ras-Raf-MEK-Erk, dabrafenib, vemurafenib, c-Jun, C-Fos, trametinib and sorafenib.

Can the Oncotrace test differentiate between benign and malignant tumour cells?

Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

I have a patient whose specific tumour appears to have resisting populations because of the overexpression of the MDR1 gene. This can be reversed by the use of inhibitors of ABG2 pumps. What do I do?

In this case, a patient could proceed with ketoconazole as a first-line treatment, and verapanib as a second-line treatment. Verapanib can contribute to a fall in blood pressure.

My patient’s report shows repair-resistance is HSP27 -10%, HSP72 -15%, HSP90 normal and sensitivity to hyperthermia. How should I interpret this?

If the detected level of heat shock protein (HSP) is above zero (normal), this shows resistance to hyperthermia or radiation. If HSP is less than zero, this shows sensitivity to hyperthermia or radiation.

How reliable is a negative circulating tumour cell test result for pancreatic adenocarcinoma patients who have no metastasis after surgery?

RGCC’s circulating tumour cell test has a negative predictive value of about 86%. This means our test will correctly return a true negative result 86% of the time.

I only have a blood sample. Is it still possible to have a test that requires both blood and tissue samples?

This depends on the cancer. With the exception of the Oncotrace test, every RGCC test can be conducted with blood sample. Certain cancers, for example, glioblastoma and other types of brain cancer, require both a blood and a tissue sample for tests.

Is a sample in formalin suitable for molecular experiments?

Once tissue is placed in formalin the cells in the tissue are no longer viable. In order to maintain viable cells, you should place the tissue in the appropriate tissue vial provided by RGCC.

It is possible to isolate DNA and/or RNA from samples, if they can be fixed and a paraffin block can be produced (FFPE tissue). Therefore only DNA/RNA tests (ChemoSnip, CGH, Gene expression-RT PCR) can be performed on these samples.

Didn’t get an answer to your query? Get in touch with your local RGCC office

Get in touch

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more